Qube Research & Technologies (QRT)’s Atrium Therapeutics RNA Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$882K	Buy	+106,532	New	+$1.26M	﹤0.01%	2690

Other funds holding RNA

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Arbiter Partners Capital Management New York $235M AUM 94.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

BlueCrest Capital Management St Helier, Jersey $2.76B AUM 15.17% 1-Year Est. Return

Quantinno Capital Management New York $106B AUM 29.93% 1-Year Est. Return

Yakira Capital Management Westport, Connecticut $397M AUM 11.81% 1-Year Est. Return

Groupe la Francaise Paris, France $8.63B AUM 33.07% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Qube Research & Technologies (QRT)'s RNA Position: Q3 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Atrium Therapeutics (RNA) in Q3 2026: 106,532 shares worth $882K. The stake represents ﹤0.01% of the portfolio and ranks #2690 among its holdings.

79 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

Qube Research & Technologies (QRT) held 106,532 shares of Atrium Therapeutics worth $882K as of Q3 2026.
Atrium Therapeutics was a new Qube Research & Technologies (QRT) position in Q3 2026.
Atrium Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #2690 holding.
79 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.